Every 10-Q that Clover Health Investments, Corp (CLOV) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CLOV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CLOV filings page.
Clover Health Investments reported a profitable first quarter of 2026, driven by strong Medicare Advantage growth. Total revenues rose to $749.2 million from $462.3 million, mainly from higher premiums as average MA membership increased to 154,607 members.
Net medical claims incurred grew to $589.6 million, reflecting the larger member base, while the Insurance Benefits Expense Ratio remained broadly stable at 86.5%. Operating leverage improved: salaries and benefits were slightly lower and Adjusted SG&A fell to 15.9% of revenues despite higher professional and broker fees tied to enrollment growth.
Clover generated net income of $27.3 million, or $0.05 per diluted share, compared with a small loss a year earlier. Non-GAAP Adjusted EBITDA increased to $40.3 million and Adjusted Net income to $39.7 million, highlighting better underlying profitability even after stock-based compensation.
Liquidity strengthened, with cash and cash equivalents of $173.3 million and total cash, cash equivalents, and investments of $418.2 million as of March 31, 2026. Operating activities provided $107.9 million of cash, supported by higher earnings and a rise in unpaid claims reserves, positioning the company to fund growth and meet regulatory capital needs.
Clover Health Investments (CLOV) filed its Q3 2025 10‑Q, reporting higher revenue but a wider loss. Total revenues were $496.7 million for the quarter, up from $331.0 million a year ago, driven primarily by higher premiums earned. Net loss from continuing operations was $24.4 million, compared with $8.8 million in the prior-year quarter, as net medical claims and operating costs increased with membership activity.
For the nine months ended September 30, 2025, revenue reached $1.44 billion and net loss from continuing operations was $36.2 million. Cash and cash equivalents were $190.1 million as of September 30, 2025. Unpaid claims declined to $140.5 million from $156.4 million at year‑end, reflecting faster claim processing. Stockholders’ equity was $340.9 million. The company also recognized fair value gains tied to a remeasured private equity investment and realized gains on warrant liquidations, recorded in other income.
Class A shares outstanding were 421.8 million and Class B 92.4 million as of September 30, 2025, with treasury stock increasing due to repurchases and tax withholdings on equity awards.
Clover Health (CLOV) Q2 2025 10-Q snapshot
Premiums climbed 34% YoY to $469.8 m, lifting total revenue to $477.6 m, yet net medical claims surged 52% to $378.0 m, pushing the medical loss ratio to ~80.5% (71% in Q2 2024). Operating loss was $10.6 m versus prior-year profit of $7.2 m; GAAP EPS fell to –$0.02.
First-half revenue rose 34% to $939.9 m while net loss narrowed to $11.9 m (–$0.02 EPS) from $16.0 m, aided by a $2.8 m favourable prior-year claims development. Stock-based compensation remained high at $52.6 m YTD.
Cash & equivalents ended at $188.6 m, down $5.9 m YTD. Operating cash flow swung to a $10.9 m outflow (vs. $79.7 m inflow last year); investing inflows of $44.5 m offset $39.5 m used for equity-related financing. Total assets were $575 m and equity improved to $344 m.
Unpaid claims declined 11% YTD to $139.7 m; investment portfolio posted a $1.8 m unrealised gain, turning OCI positive. Weighted-average diluted shares stood at 509 m.
Management continues to expand Clover Assistant and Counterpart Health SaaS but flags medical cost inflation, RADV audit exposure and regulatory uncertainty as key risks.